Ih Chang

7.9k total citations · 1 hit paper
56 papers, 5.2k citations indexed

About

Ih Chang is a scholar working on Epidemiology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Ih Chang has authored 56 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Epidemiology, 14 papers in Oncology and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Ih Chang's work include Polyomavirus and related diseases (13 papers), Multiple Sclerosis Research Studies (12 papers) and Pneumonia and Respiratory Infections (12 papers). Ih Chang is often cited by papers focused on Polyomavirus and related diseases (13 papers), Multiple Sclerosis Research Studies (12 papers) and Pneumonia and Respiratory Infections (12 papers). Ih Chang collaborates with scholars based in United States, United Kingdom and Germany. Ih Chang's co-authors include Robert Kohberger, George R. Siber, Jill Hackell, Dace V. Madore, Frank Malinoski, Henry R. Shinefield, Steven Black, Paula Ray, Bruce Fireman and Keith P. Klugman and has published in prestigious journals such as The Lancet, Neurology and PEDIATRICS.

In The Last Decade

Ih Chang

53 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children

2000 1.8k citations Steven Black, Henry R. Shinefield et al. The Pediatric Infectious Disease Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ih Chang United States	25	3.8k	2.1k	495	448	425	56	5.2k
Chiara Azzari Italy	38	2.7k 0.7×	540 0.3×	589 1.2×	114 0.3×	524 1.2×	251	5.1k
Johannes G. Liese Germany	35	2.5k 0.6×	996 0.5×	947 1.9×	93 0.2×	167 0.4×	133	4.3k
Richard A. Insel United States	39	2.0k 0.5×	773 0.4×	1.5k 3.1×	242 0.5×	195 0.5×	111	5.8k
Maria Paris United States	27	1.1k 0.3×	786 0.4×	578 1.2×	62 0.1×	399 0.9×	73	2.4k
Klaus Dalhoff Germany	37	1.5k 0.4×	666 0.3×	1.1k 2.2×	58 0.1×	270 0.6×	141	4.2k
Kurt Olsen United States	33	2.3k 0.6×	1.9k 0.9×	697 1.4×	22 0.0×	503 1.2×	56	4.0k
Martin Witzenrath Germany	39	1.2k 0.3×	355 0.2×	1.1k 2.3×	160 0.4×	313 0.7×	182	5.0k
James D. Connor United States	45	3.3k 0.9×	350 0.2×	371 0.7×	72 0.2×	507 1.2×	152	6.1k
Carlo Contini Italy	25	798 0.2×	223 0.1×	205 0.4×	214 0.5×	233 0.5×	169	2.3k
Tran Thi Hong Chau Vietnam	38	1.6k 0.4×	891 0.4×	743 1.5×	40 0.1×	1.3k 3.1×	77	5.0k

Countries citing papers authored by Ih Chang

Since Specialization

Citations

This map shows the geographic impact of Ih Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ih Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ih Chang more than expected).

Fields of papers citing papers by Ih Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ih Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ih Chang. The network helps show where Ih Chang may publish in the future.

Co-authorship network of co-authors of Ih Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Ih Chang. A scholar is included among the top collaborators of Ih Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ih Chang. Ih Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Takahashi, Koji, Meera Tugnait, Ih Chang, et al.. (2024). EMPOWERing the Next-Generation: A Phase 2 Program to Evaluate Emraclidine, a Selective M4 Positive Allosteric Modulator (PAM), for the Treatment of Schizophrenia. CNS Spectrums. 29(5). 495–495.

Krystal, John H., John M. Kane, Christoph U. Correll, et al.. (2022). Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. The Lancet. 400(10369). 2210–2220. 77 indexed citations

Elliott, Colm, Douglas L. Arnold, Chunlei Ke, et al.. (2020). Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions. American Journal of Neuroradiology. 41(9). 1584–1591. 33 indexed citations

Ryerson, Lana Zhovtis, John Foley, Ih Chang, et al.. (2020). Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) than every-4-week (Q4W) dosing: Updated analysis of the TOUCH® Prescribing Program database (1988). Neurology. 94(15_supplement). 2 indexed citations

Butzkueven, Helmut, Ludwig Kappos, Heinz Wiendl, et al.. (2020). Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Journal of Neurology Neurosurgery & Psychiatry. 91(6). 660–668. 99 indexed citations

Ryerson, Lana Zhovtis, John Foley, Ih Chang, et al.. (2019). Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 93(15). e1452–e1462. 116 indexed citations

Campbell, Nolan, Jeffrey A. Cohen, Heinz Wiendl, et al.. (2019). Evaluating the efficacy and safety of 6-week extended interval dosing of natalizumab via a prospective, controlled, randomized, open-label, rater-blinded phase 3b study (P3.2-095). Neurology. 92(15_supplement).

Zhu, Bing, Peter A. Calabresi, Gavin Giovannoni, et al.. (2019). Phase 2 AFFINITY Trial Evaluates Opicinumab in a Targeted Population of Patients With Relapsing Multiple Sclerosis: Rationale, Design and Baseline Characteristics (P3.2-072). Neurology. 92(15_supplement). 4 indexed citations

Elkins, Jacob, Roland Veltkamp, Joan Montaner, et al.. (2017). Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. The Lancet Neurology. 16(3). 217–226. 160 indexed citations

10.

Ho, Pei‐Ran, et al.. (2017). Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. The Lancet Neurology. 16(11). 925–933. 209 indexed citations

11.

Fox, Robert J., Andrew Chan, Ralf Gold, et al.. (2016). Characterization of Absolute Lymphocyte Count Profiles in MS Patients Treated with Delayed-Release Dimethyl Fumarate: Considerations for Patient Management (P2.099). Neurology. 86(16_supplement). 5 indexed citations

12.

Watson, Catherine E., Lise Kjems, Surya Ayalasomayajula, et al.. (2010). Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. Journal of Lipid Research. 52(2). 361–373. 126 indexed citations

13.

Berwaerts, Joris, et al.. (2009). The Effects of Paroxetine on the Pharmacokinetics of Paliperidone Extended-release Tablets. Pharmacopsychiatry. 42(4). 158–163. 32 indexed citations

14.

O’Brien, Katherine L., Lawrence H. Moulton, Raymond Reid, et al.. (2003). Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. The Lancet. 362(9381). 355–361. 299 indexed citations

15.

Moulton, Lawrence H., Katherine L. O’Brien, Robert Kohberger, et al.. (2001). Design of a Group-Randomized Streptococcus pneumoniae Vaccine Trial. Controlled Clinical Trials. 22(4). 438–452. 48 indexed citations

16.

Black, Steven, Jill Hackell, George R. Siber, et al.. (2000). Efficacy, Safety, and Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine in Children. The American Journal of Managed Care. 6. 3 indexed citations

17.

Black, Steven, Henry R. Shinefield, Bruce Fireman, et al.. (2000). Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. The Pediatric Infectious Disease Journal. 19(3). 187–195. 1817 indexed citations breakdown →

18.

Mbelle, Nontombi, Robin Huebner, Avril D. Wasas, et al.. (1999). Immunogenicity and Impact on Nasopharyngeal Carriage of a Nonavalent Pneumococcal Conjugate Vaccine. The Journal of Infectious Diseases. 180(4). 1171–1176. 431 indexed citations

19.

Shinefield, Henry R., Steven Black, Paula Ray, et al.. (1999). Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. The Pediatric Infectious Disease Journal. 18(9). 757–763. 234 indexed citations

20.

Graves, David A., et al.. (1990). Hydralazine dose-response curve analysis. Journal of Pharmacokinetics and Biopharmaceutics. 18(4). 279–291. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact